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The aim of this study was to investigate the pleural and systemic expression of interleukin-18 (IL-18) in
patients with pleural effusions (PEs), and the effects of the cytokine in mouse pleural space.
One hundred and sixty patients, 23 with pleural effusions (PEs) due to heart failure, 60 malignant, 25
parapneumonic/empyemas, 15 tuberculous and 37 with exudates of miscellaneous etiologies were
included in the study. Pleural ﬂuid (PF) and serum IL-18 content was determined using ELISA. IL-18
was injected intrapleurally in mice and pleural inﬂammation was assessed using pleural lavage.
The highest PF IL-18 levels were observed in parapneumonic PEs and the lowest PF IL-18 levels in
patients with exudates of miscellaneous aetiologies and transudates. PF IL-18 levels were signiﬁcantly
higher in patients with empyemas compared to those with uncomplicated (p = 0.009) or complicated
(p = 0.028) parapneumonic effusions, while serum levels did not differ signiﬁcantly among the three
groups. Pleural IL-18 content was higher than that of blood only in patients with empyemas. In patients
with pleural exudates of all etiologies and in those with parapneumonic PEs/empyema, PF IL-18 levels
were correlated with markers of acute pleural inﬂammation such as the percentage of PF neutrophils,
PF LDH and PF/serum LDH ratio, low PF glucose and PF/serum glucose ratio and low PF pH. In mice,
intrapleural IL-18 caused neutrophil-predominant pleural inﬂammation.
In conclusion, IL-18 is linked to the intensity of neutrophilic pleural inﬂammation in patients with PEs,
it is up-regulated in the pleural space of patients with empyema and it stimulates the accumulation of
neutrophils in mouse pleura.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Pleural effusion (PE) is a common manifestation of a wide range
of thoracic or systemic abnormalities. Pleural ﬂuid (PF) may accu-
mulate as a result of hydrostatic and/or osmotic pressure imbal-
ances across intact endothelial and mesothelial membranes
(transudative PE), or results from increased pleural vascular per-
meability (exudative PE) [1] ascribed to pro-inﬂammatory and
pro-permeability factors produced in the pleural cavity or derived
from systemic circulation [2]. Pleural exudates are caused by
inﬂammatory and malignant diseases and may pose an importantr Ltd.
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Open access under CC BY licensediagnostic and therapeutic problem. Getting further insights into
the role of different mediators which contribute to the pathogene-
sis of exudative PEs of different etiologies might help to develop
novel diagnostic and therapeutic tools.
Interleukin-18 (IL-18) is a pleiotropic inﬂammatory cytokine
that is mainly produced by activated macrophages, neutrophils,
dendritic cells, and Kupffer cells [3–5]. IL-18 is an important com-
ponent of immune response to infectious agents [4–12] and it is
up-regulated in autoimmune inﬂammatory diseases [13,14]. Even
though IL-18 is involved in the regulation of inﬂammation and
stimulates vascular hyper-permeability [15], both hallmarks of
exudative PEs, very little is known about its role in pleural diseases.
We here aimed to explore the pleural and systemic expression
of IL-18 in patients with PEs of various etiologies and to investigate
the effect of pleural propagation of IL-18 in mice. It was hypothe-
sized that: (i) IL-18 levels would be elevated in the pleural cavity of
patients with exudative compared to those with transudative PEs,
(ii) among exudates, IL-18 levels would be higher in the PEs of
infectious etiology compared to those with malignant PEs, and
(iii) intrapleurally administered IL-18 would provoke pleural
inﬂammation in mice..
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Since 2006 we maintain a bank of pleural ﬂuid and serum sam-
ples and a corresponding database of patients with pleural effu-
sions in two University Departments of Athens Medical School:
the 1st Department of Critical Care and Pulmonary Services, Evan-
gelismos Hospital and the 2nd Department of Pulmonary Medicine,
Atticon Hospital, Athens Greece [16]. This work has been approved
by the Ethics Committees of both hospitals.
For the study presented herewe used samples obtained between
January 2007 and September 2009. Patients without a deﬁnite diag-
nosis, those with hemothorax/chylothorax, those with more than
one possible etiology for the PE and those without a paired serum
sample were excluded. PEs were attributed to a certain etiology
using established clinical, imagingmicrobiological and pathological
criteria as described previously [17] and were categorized as exu-
dates or transudates according to Light’s criteria [18]. Parapneu-
monic PEs were termed uncomplicated when resolution occurred
with antibiotics and complicated when pleural drainage was re-
quired. Pleural empyema was deﬁned as the presence of pus in
the pleural space. IL-18 levels were determined using a commercial
enzyme-linked immunosorbent assay (MBL International Corpora-
tion) following the manufacturer’s instructions. The investigator
who performed the measurements was blinded as to the patients’
diagnosis. The lower detection limit was 12.5 pg/ml and this value
was given to samples with undetectable IL-18 levels.
2.1. Animal studies
Eight to 10 week-old C57BL/6 mice (Hellenic Pasteur Institute,
Athens, Greece) were inbred at the General Hospital ‘‘Evangelis-
mos’’ (Athens, Greece). Experiments were approved by the Veteri-
nary Administration Bureau, Prefecture of Athens, Greece.Table 1
Pleural ﬂuid features in patients with PEs of different etiologies.
Malignancya Parapneumonicb
(n = 60) (n = 25)
Red blood cells (per lL) 2800 1270
(20–3,20,000) (120–1,28,000)
Nucleated cells (per lL) 1525 2700
(85–16,200) (500–9,10,000)
Mononuclear cells (%) 44 (5–90) 18 (0–88)
Neutrophils (%) 2 (0–65) 73 (0.1–99)
Lymphocyte (%) 45 (3–94) 2 (0–77)
LDH (IU/L) 597 1721
(87–4511) (259–110610)
LDH PF/serum ratio 1.57 3.4
(0.44–6.35) (0.6–374)
Glucose (mg/dl) 105 52
(2–312) (1–199)
Glucose PF/serum ratio 1 0. 6
(0.02–1.7) (0–1.3)
pH 7.36 7.17
(7.1–7.58) (6.18–7.8)
Protein (g/dl) 4.5 4.2
(2.8–7.8) (2.2–6.5)
Protein PF/serum ratio 0.7 0.67
(0.44–1.0) (0.37–0.9)
Values are expressed as median (IQR).
a Non-small cell lung cancer [27]; Small cell lung cancer [2]; malignant pleural meso
lymphoma [2]; breast cancer [7]; thyroid cancer [2]; gastric cancer [1]; colon cancer [1]
b Uncomplicated [9]; complicated [7]; empyema [9].
c post-traumatic [3], uremic [3], viral [4], post-coronary-artery-bypass-grafting [6], s
myolipoma [1], benign asbestos pleural effusion [4], pulmonary emboli [7], and hashimIntrapleural injection of 1 lg IL-18 (Recombinant Mouse IL-18,
R&D Systems, Minneapolis, Minnesota) or PBS–BSA 1% were per-
formed in anesthetized mice as described elsewhere [19]. Mice
were sacriﬁced with sevoﬂuranium overdose, 4 or 24 h following
the intrapleural injections and pleural lavage (PL) was performed
through the diaphragm using 1 ml heparinized saline [20].
Twenty-three mice were sacriﬁced 4 h after the intrapleural injec-
tions (11 control and 12 IL-18 injected mice) and 24 mice were sac-
riﬁced in 24 h (10 control and 14 IL-18 injected mice). PL samples
contaminated with blood were excluded from analysis. Pleural
nucleated cell differential count was then assessed by manually
counting 500 cells in May-Grünwald-Giemsa stained cytospins,
by two independent observers, blinded as to the treatment group.
The average values were reported.
2.2. Statistical analysis
Values are reported as the mean ± standard error of the mean
(SEM) when normally distributed or as the median (interquartile
range) when not normally distributed. The independent-value
T-test, the Wilcoxon, the Kruskal–Wallis and the Mann–Whitney
tests were used to assess the difference between different groups,
as appropriate. A p < 0.05 was considered to be statistically signif-
icant. The Spearman test was used to assess the correlation be-
tween variables. For all the above analyses, a statistical software
package (SPSS, version 11.0; SPSS Inc; Chicago, IL) was used.
3. Results
3.1. IL-18 levels in patients with pleural effusions
Samples and clinical data from 160 patients with mean ± SEM
age 63.9 ± 18 years and a male/female ratio of 1.83 were evaluatedTuberculosis Other exudatesc Heart failure
(n = 15) (n = 37) (n = 23)
2600 4290 800
(80–1,20,000) (200–1,94,000) (40–72,000)
3100 2490 1130
(960–8000) (65–16,000) (80–3510)
19 (7–82) 39 (7–91) 60 (32–84)
2 (0–32) 3.1 (0–84) 3.2 (0–30)
74 (6–93) 41 (0.5–92) 31 (0–63)
853 399 204
(430–2516) (14–2357) (52–813)
2.1 1.25 0.43
(1–7.1) (0.04–8.2) (0.13–0.7)
89 97 131
(25–106) (17–225) (56–493)
1 1.0 1.2
(0.37–1.15) (0.19–1.9) (0.8–1.96)
7.35 7.37 7.4
(7.1–7.40) (7.13–7.47) (7.25–7.5)
5.2 4.6 2.4
(4.6–5.7) (1.6–7) (1.5–3.9)
0.72 0.66 0.39
(0.65–0.87) (0.25–1) (0.23–0.58)
thelioma [9]; chronic lymphocytic leukaemia [1]; chronic myeloid leukaemia [1];
; ovarian cancer [1]; cholaggeiocarcinoma [1]; and unknown primary [3].
ystemic lupus erythematous [5], reumatide arthritis [2], cholecystitis [1], aggeio-
oto thyroiditis [1].
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dates [405 (12.5–7690) pg/ml vs 318 (12.5–820) pg/ml, p = 0.048].
Serum IL-18 levels did not differ signiﬁcantly between transudates
and exudates [520 (12.5–1792) pg/ml to 366 (12.5–1856) pg/ml,
p > 0.05].
The median PF and serum IL-18 levels per diagnostic group are
depicted in Fig. 1. The highest PF IL-18 content was observed in
parapneumonic PEs/empyemas and the lowest PF IL-18 levels in
patients with exudates of miscellaneous etiologies and transu-
dates. PF IL-18 levels were signiﬁcantly lower than corresponding
serum levels in patients with exudates of miscellaneous etiologies
[252 (12.5–361) pg/ml vs 408 (243–628) pg/ml, p = 0.027] and
transudates [310 (141–468) pg/ml vs 530 (229–683) pg/ml,
p = 0.012]. A signiﬁcant correlation between PF and serum IL-18
levels was observed in every group: malignant PEs, r = 0.581,
p < 0.001, parapneumonic PEs/empyemas r = 0.454, p = 0.023,
tuberculous PEs, r = 0.537, p = 0.039, other PEs, r = 0.682,
p < 0.001 and transudates, r = 0.563, p = 0.005.3.2. Pleural but not serum IL-18 is up-regulated in pleural empyemas
To obtain further insights into the expression of IL-18 during
the progression of reactive, sterile parapneumonic PEs to empy-
ema, we compared the PF and serum levels in patients with
uncomplicated parapneumonic PEs, complicated parapneumonic
PEs and frank pleural sepsis (empyema). PF IL-18 levels were sig-
niﬁcantly higher in patients with empyemas than in those with
uncomplicated (p = 0.009) or complicated (p = 0.028) parapneu-
monic effusions, while serum levels did not differ signiﬁcantly
among the three groups (Fig. 2). PF IL-18 levels were signiﬁcantly
higher than the corresponding serum levels in patients with empy-
ema (p = 0.04) but not in those with serous parapneumonic
effusions.
To assess whether the difference of pleural IL-18 content be-
tween the patients with parapneumonic PEs/empyema and those
with PEs of all other exudative etiologies was dominated by the
presence of empyema in infectious group, we compared PF IL-18
content in different sub-groups of parapneumonic PEs/empyemas
to that of other categories of exudative PEs. IL-18 levels were not
signiﬁcantly different between uncomplicated parapneumonic
PEs and malignant PEs [372 (12.5–1468) pg/ml vs 358 (12.5–
1290) pg/ml, p > 0.05], tuberculous PEs [372 (12.5–1468) pg/ml
vs 426 (12.5–1093) pg/ml, p > 0.05], and exudates of miscellaneous
etiologies [372 (12.5–1468) pg/ml vs 243 (12.5–1069) pg/ml,Fig. 1. PF (A) and serum (B) IL-18 levels in patients with malignant pleural effusions (M
effusions (TB), exudates of miscellaneous etiologies (other), and heart failure (HF).p > 0.05]. In complicated parapneumonic PEs, PF IL-18 levels were
higher than those observed in exudates of miscellaneous etiologies
[563 (357–1093) pg/ml vs 243 (12.5–1069) pg/ml, p = 0.03] and
they did not signiﬁcantly differ from those observed in malignant
and tuberculous PEs. A statistically signiﬁcant difference in the
PF IL-18 levels was found between empyemas and malignant PEs
[2424 (506–7690) pg/ml vs 358 (12.5–1290) pg/ml, p = 0.001],
empyemas and tuberculous PEs [2424 (506–7690) pg/ml vs 426
(12.5–2090) pg/ml, p = 0.007], and empyemas and exudates of
other etiologies [2424 (506–7690) pg/ml vs 243 (12.5–1069) pg/
ml, p = 0.001].3.3. PF IL-18 levels are associated with markers of pleural
inﬂammation
PF IL-18 levels were related to PF features of pleural inﬂamma-
tion when all patients with pleural exudates were considered: PF
IL-18 levels were signiﬁcantly correlated with PF LDH (r = 0.218,
p = 0.018) and PF/serum LDH ratio (r = 0.258, p = 0.005), and inver-
sely correlated with PF glucose (r = 0.238, p = 0.01), PF/serum glu-
cose ratio (r = 0.229, p = 0.013), and PF pH (r = 0.343, p < 0.001).
Furthermore, PF IL-18 levels were correlated with the percentage
of PF neutrophils (r = 0.216, p = 0.019). Similarly, in parapneumon-
ic PEs/empyemas, PF IL-18 levels were correlated with PF nucle-
ated cell counts (r = 0.594, p = 0.006), the percentage of PF
neutrophils (r = 0.618, p = 0.004), (Fig. 3A), PF LDH (r = 0.471,
p = 0.036) and PF/serum LDH ratio (r = 0.602, p = 0.005), and inver-
sely correlated with the percentage of lymphocytes (r = 0.669,
p = 0.001), with PF glucose (r = 0.509, p = 0.022), PF/serum glu-
cose ratio (r = 0.452, p = 0.046), and PF pH (r = 0.645,
p = 0.003), (Fig. 3B). No signiﬁcant correlation between blood IL-
18 content and blood white cell counts or blood neutrophils (%)
was found when either patients with exudates or patients with
parapneumonic pleural effusions and empyema were examined.3.4. Intrapleural administration of IL-18 elicits a neutrophilic pleural
inﬂammatory response
The close relationship between IL-18 content and the number of
neutrophils in parapneumonic PEs might suggest a chemotactic ef-
fect of IL-18. To test this possibility we explored whether direct
intrapleural administration of the cytokine in mice could induce
pleural neutrophilia. This proved to be the case: as shown in
Fig. 4A, 4 h following IL-18 injection, the percentage of PL neutro-AL), parapneumonic pleural effusions or empyema (PRP/EMP), tuberculous pleural
Fig. 2. PF and serum IL-18 levels in patients with uncomplicated (UCPPEs) and
complicated (CPPEs) parapneumonic pleural effusions and empyemas.
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(p = 0.038). Similarly, 24 h post-treatment the percentage of PL
neutrophils was 5.2 ± 6% in control and 15.6 ± 12.8% in mice in-
jected with IL-18, respectively (p = 0.024) (Fig. 4B). PL percentage
of large mononuclear cells, lymphocytes and eosinophils did not
differ signiﬁcantly between IL-18 treated and control animals in
either time point.4. Discussion
In the present study we determined the PF and serum IL-18
content in patients with PEs and examined whether IL-18 induces
pleural inﬂammation in mice. The main ﬁndings were: (i) The
highest PF IL-18 levels were observed in parapneumonic PEs, espe-
cially in empyemas; (ii) pleural IL-18 content was higher than that
of blood only in patients with empyemas; (iii) in patients with
pleural exudates and in those with parapneumonic PEs/empyema,
PF IL-18 levels were correlated with markers of pleural inﬂamma-
tion such as the percentage of PF neutrophils, PF LDH and PF/serum
LDH ratio, low PF glucose and PF/serum glucose ratio and low PFFig. 3. Correlations between IL-18 levels in parapneumonic pleural epH; and (iv) intrapleural IL-18 provoked a rapid pleural inﬂamma-
tory response characterized by the accumulation of neutrophils in
mice.
This is practically the ﬁrst study that examined both pleural and
systemic IL-18 expression in a large cohort of patients with PEs of a
wide range of etiologies and the ﬁrst attempt to assess whether IL-
18 stimulates pleural inﬂammation in mice. The most striking ﬁnd-
ing of the study was the increased IL-18 levels in infectious PEs,
with the highest expression observed in empyemas. Probably be-
cause IL-18 is a Th-1 cytokine, and Th-1 immune response is cen-
tral to the immunopathology of tuberculosis, previous studies
connecting IL-18 with pleural disease had focused in tuberculous
PEs. These studies included much lower numbers of patients and
demonstrated elevated levels of IL-18 in tuberculous PEs compared
to non-tuberculous PEs [21–23]. This observation was not con-
ﬁrmed by our study, although we detected relatively high PF IL-
18 levels in tuberculous PEs. The discrepancy between the present
and previous studies should most likely be ascribed to the fact that
the previous studies included a very limited number of patients
with parapneumonic effusions (form 0 to 4 patients) who were
not even examined as a separate group. From a clinical point of
view, PF IL-18 does not seem to be useful in discriminating be-
tween different causes of pleural effusions with the possible excep-
tion of empyema which, however is a diagnosis easily made by the
macroscopic appearance of the ﬂuid.
In contrast to their limited clinical signiﬁcance, our ﬁndings
hold certain implications on the possible role of IL-18 in the path-
ophysiology of parapneumonic PEs. While early-stage parapneu-
monic PEs are reactive, serous in appearance and sterile, they
sometimes get infected and progress to empyemas. During this
process, pleural inﬂammation is getting progressively more
intense as manifested by the increasing numbers of invading
inﬂammatory cells, mainly neutrophils, increasing pleural LDH
and decreasing pleural glucose and pH. Therefore, our ﬁndings of
high pleural IL-18 content in empyema compared to the serous
parapneumonic PEs, along with the close correlation between
pleural IL-18 levels and PF markers of inﬂammation suggest that
IL-18 might be functionally related to the escalation of bacteria-re-
lated pleural inﬂammation. Then, where does pleural IL-18 come
from? In contrast to all other types of PEs in which PF IL-18 levels
were lower or comparable to those of blood, in empyemas, pleural
exceeded systemic IL-18 content indicating local pleural IL-18
production by either resident pleural mesothelial [23] or inﬂam-
matory [3–5] cells, an observation that is in agreement with affusions with neutrophil percentage (A) and pleural ﬂuid pH (B).
Fig. 4. Neutrophilic pleural inﬂammatory response in mice 4 and 24 h after
intrapleural administration of IL-18.
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pneumoniae in the pleural cavity is associated with elevated PF
IL-18 levels [24].
The functional consequences of IL-18 expression in parapneu-
monic effusions remain elusive. Abundant pleural IL-18 might be
part of the protective anti-infectious pleural immune response. It
should be however noted that while IL-18 has been recognized
as a critical regulator of protective immunity against intracellular
bacteria [25], evidence on its role in host defense against extracel-
lular bacteria, by far the most common pathogens related to pleu-
ral sepsis, is controversial [26,9,10]. On the other hand, keeping in
mind that IL-18 possesses vascular hyper-permeability [15] and
pro-ﬁbrinolytic [27] properties, it is reasonable to assume that
IL-18 could enhance pleural ﬂuid production and promote
empyema-associated pleural ﬁbrosis thus contributing to
empyema histophathology.
The close correlation between the number of pleural neutro-
phils and the PF IL-18 levels denotes that IL-18 may be either the
reason or the result of the pleural accumulation of neutrophils.
In relation to this, neutrophils have been previously shown to be
an important source of IL-18 [28]. However, IL-18 is also a potent
chemo-attractant of neutrophils [29,30]. We here demonstrated
for the ﬁrst time that intrapleural IL-18 injection results to a rapid
pleural accumulation of neutrophils into mouse pleura, an obser-
vation favouring the possibility that excessive pleural IL-18 stimu-
lated neutrophil chemotaxis. Summing up the issues discussed in
the last three paragraphs, we could propose that IL-18 is involved
in the escalation of pleural inﬂammation during the progression of
a parapneumonic effusion to empyema and that its role in this pro-
cess is related to its chemotactic activity on neutrophils. However,
the observed close correlation between pleural IL-18 content and
markers of pleural inﬂammation when all patients with pleural
exudates are considered, implies that IL-18 may also contribute
to the pleural inﬂammation in malignant and inﬂammatory PEs
that are not related to pneumonia.
In conclusion, we have shown that IL-18 is locally over-ex-
pressed in the pleural cavity of patients with empyema and it is
associated with the enhancement of pleural inﬂammation, an ef-
fect that is at least partly related to the stimulation of the pleural
inﬂux of neutrophils. However, the cellular source of IL-18 in the
pleural cavity of patients with pleural infection could not be estab-lished in the present study. Future in vivo functional studies may
deﬁne whether the primary role of IL-18 in pleural infection is
protective or it mainly contributes to empyema histopathology
and therefore could be therapeutically targeted to prevent pleural
damage and ﬁbrosis.
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